Frontlight ResearchEarly access
Enrolling by invitationPhase 2
An Open-label Study With Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis
Key facts
- Who runs it
- Oruka Therapeutics, Inc.
- Where
- Fountain Valley, Milford, New Brighton, Warrenton, and Wilmington, United StatesSee the 5 sitesAlso in 1 other country, 3 sites
- Trial code
- Status
- Enrolling by invitation
- Phase
- Phase 2
- People taking part
- 160 people, planned
- Started
- 26 Oct 2026
- Expected to end
- 1 Sept 2029
- Type of study
- Interventional, 3 groups
- Treatments tested
- ORKA-002
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years to 79 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Signed informed consent by participants from previous trial choosing to transition into the Open-label study
- Participants who have successfully completed the preceding trial
- For women of childbearing potential, must have a negative urine pregnancy test at Baseline visit
- For women of childbearing potential and fertile male participants with a partner of childbearing potential must be willing to continue to use highly effective contraception
Who cannot take part
- Participants who experienced any adverse events with ORKA-002 in the preceding trial that led to permanent investigational medicinal product discontinuation or, in the opinion of the Investigator, would preclude continued treatment with ORKA-002
- Participants whom the Investigator feels would not benefit from treatment with open-label ORKA-002
- Participants who have developed guttate, erythrodermic or pustular psoriasis or drug-induced psoriasis (as diagnosed by the Investigator), during the preceding trial
- Participants who, while in ORKA-002-212, developed a new intercurrent illness or diagnosis/suspected diagnosis which, in the opinion of the Investigator, indicates that continued treatment and/or participation in the study is not in the participant's best interest
- Any clinically significant laboratory abnormality based on the last available lab results received during the preceding trial, that, according to the Investigator's medical assessment, precludes them from continued treatment with ORKA-001
- Participant is pregnant or breastfeeding
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 79 years old?
Where in United States
Also in 1 other country, 3 sites
- Fountain Valley, CaliforniaHospital not named in the registryEnrolling by invitation
- Milford, MassachusettsHospital not named in the registryEnrolling by invitation
- New Brighton, MinnesotaHospital not named in the registryEnrolling by invitation
- Warrenton, OregonHospital not named in the registryEnrolling by invitation
- Wilmington, North CarolinaHospital not named in the registryEnrolling by invitation
About the trial
What the trial wants to find out
An open-label study with maintenance dosing to evaluate the long-term safety and efficacy of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
The 3 groups in the trial
- ORKA-002 (High Dose)Treatment being tested
Participants will receive ORKA-002 every 6 moinths per protocol.
Treatment: ORKA-002
- ORKA-002 (Low Dose)Treatment being tested
Participants will receive ORKA-002 every 6 months per the protocol.
Treatment: ORKA-002
- ORKA-002 (Mid-Dose)Treatment being tested
Participants will receive ORKA-002 every 6 moinths per the protocol
Treatment: ORKA-002
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open-label Study With Maintenance Dosing to Evaluate the Long-term Safety, Tolerability, and Efficacy of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis
- Fit questions
- Built from NCT07933783, who can take part
- Record updated
- 12 November 2026